Optimal drug therapy for patients with stenocardia and its impact on mortality

Cover Page

Cite item

Full Text

Abstract

In this clinical seminar (lecture) we argue the urgency to optimize the drug therapy in patients with stable angina pectoris. Today the quality of their treatment remains lower than it could be. In majority of cases the applied drug therapy does not allow to control the risk factors of inappropriate prognosis. Inadequate treatment of angina pectoris contributes to very high mortality rate due to cardiac diseases in Russian Federation. Prescription of drugs with proven positive effect is often based on non-optimal schemes. Moreover, there is a wide-spread tendency to prescribe metabolic drugs to patients with cardiovascular pathology and other diseases notwithstanding the fact that the pharmacoeconomic validity of such drugs remains to be demonstrated.

About the authors

N. A Mazur

Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation

Email: mazur@land.ru
д-р мед. наук, проф., зав. каф. кардиологии ФГБОУ ДПО РМАНПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

References

  1. http://www.gks.ru/wps/wcm/connect/rosstatmain/rosstat/ru/statistics/population/demography
  2. The Academic Research Organization Consortium for Continuing Evaluation of Scientific Studies - Cardiovascular (ACCESS CV). Sharing Data from Cardiovascular Clinical Trials - A Proposal. N Engl J Med 2016; 375: 407-9.
  3. Саютина Е.В., Чигинева В.В., Золозова Е.А. и др. Контроль ишемии миокарда у больных стенокардией напряжения с многососудистым атеросклеротическим поражением. Кардиология. 2012; 8: 15-9.
  4. Карлова Н.А., Золозова Е.А., Пшеницин А.И. и др. Оценка терапевтической эффективности и безопасности оригинального препарата бисопролола и его дженерика бипрола у больных стабильной стенокардией. Кардиология. 2015; 1: 23-8.
  5. Euro Heart Survey of stable angina: prospective observational study. Eur Heart J 2005; 26: 1011-22.
  6. ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. 2013.
  7. ESC guidelines stable coronary artery disease. Eur Heart J 2013; 34 (38): 2927-8.
  8. PEGASUS-TIMI 54 Steering Committee and Investigators. Long - Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med 2015; 372: 1791-800.
  9. Serebruany V.L. The TRITON versus PLATO trials: differences beyond platelet inhibition. Thromb Haemost 2010; 103 (2): 259-61.
  10. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348 (9038): 1329-39.
  11. Lee M, Wu Y.L, Saver J.L et al. Is clopidogrel better than aspirin following breakthrough strokes. A retrospective cohort study. BMJ Open 2014; 4 (12): e006672.
  12. Мазур Н.А. Антиагрегантная терапия у больных ишемической болезнью сердца: нерешенные проблемы. Кардиология. 2016; 1: 66-70.
  13. Everly M.J, Heaton P.C, Cluxton R.J. Beta - Blocker Underuse in Secondary Prevention of Myocardial Infarction. Ann Pharmacother 2003; 38: 286-93.
  14. Le S.J. Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry. Circ Heart Fail 2015; 8 (5): 871-9.
  15. Flather M.D, Shibata M.C, Coats A.J et al; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26 (3): 215-25.
  16. Мазур Н.А. Внезапная смерть больных ишемической болезнью сердца. М.: Медицина, 1985; с. 121-42.
  17. Hansen J.F. Treatment with verapamil after an acute myocardial infarction. Review of the Danish studies on verapamil in myocardial infarction (DAVIT I and II). Drugs 1991; 42 (Suppl. 2): 43-53.
  18. Rehnqvist N, Hjemdahl P, Billing E et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17 (1): 76-81.
  19. The Multicenter Diltiazem Postinfarction Trial Research Group The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl Med 1988; 319 (7): 385-92.
  20. Poole-Wilson P.A, Lubsen J, Kirwan B.A et al; Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long - acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364 (9437): 849-57.
  21. Мазур Н.А. Практическая кардиология. М.: Медпрактика-М, 2015; с. 109-37.
  22. Хоринака Ш. Влияние никорандила на частоту сердечно - сосудистых событий у пациентов с коронарной болезнью сердца. Рос. кардиол. журн. 2011; 2 (88): 82-90.
  23. Sakata Y, Nakatani D, Shimizu M et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction. J Cardiol 2012; 59 (1): 14-21.
  24. IONA Study Group. Impact of nicorandil in angina: subgroup analyses. Heart 2004; 90 (12): 1427-30.
  25. Stoschitzky K, Rezkalla S.H, Klone R.A. No evidence of nitrate tolerance with Nicorandil. Eur Heart J 2012; 32 (Abstract Supplement): 470.
  26. Sekiya M, Sato M, Funada J et al. Effects of the long - term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 2005; 46 (1): 63-7.
  27. Patel D.J, Purcell H.J, Fox K.M on behalf of the CESAR 2 investigation. Cardioprotection by opening of the KATP channel in unstable angina. Eur Heart J 1999; 20: 51-7.
  28. Eguchi Y, Takahari Y, Higashijima N et al. Nicorandil Attenuates FeCl3-Induced Thrombus Formation Through the Inhibition of Reactive Oxygen Species Production. Circ J 2009; 73 (3): 554-61.
  29. Izumiya Y, Kojima S, Araki S et al. Long - term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. Atherosclerosis 2011; 214 (2): 415-21.
  30. Markham A, Plosker G.L, Goa K.L. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardio - protective effects. Drugs 2000; 60: 955-74.
  31. Kasama S, Toyama T, Sumino H et al. Long - term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction. J Nucl Med 2007; 48 (10): 1676-82.
  32. Kasama S, Toyama T, Hatori T et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy. Am Heart J 2005; 150 (3): 477.e1-477.e8.
  33. Evans M, Carrero J.J, Szummer K, Akerblom A. Angiotensin - Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction. J Am Coll Cardiol 2016; 67: 1687-97.
  34. Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 2000; 1 (1): 18-20.
  35. Campbell D.J. A review of Perindopril in the reduction of cardiovascular events. Vasc Health Risk Manag 2006; 2 (2): 117-24.
  36. Tardif J.C, Ponikowski P, Kahan T. ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta - blocker therapy: a 4-month, randomized, placebo - controlled trial. Eur Heart J 2009; 30 (5): 540-8.
  37. Fox K, Ford I, Steg P.G et al; SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371 (12): 1091-9.
  38. Tanboğa İ.H, Topçu S, Aksakal E et al. The Risk of Atrial Fibrillation With Ivabradine Treatment: A Meta - analysis With Trial Sequential Analysis of More Than 40 000 Patients. Clin Cardiol 2016; 39 (10): 615-20.
  39. Szwed H, Sadowski Z, Elikowski W et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double - blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001; 2 (24): 2267-74.
  40. The EMIP-FR Group. Effect of 48-h intravenous trimetazidine on short - and long - term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double - blind, placebo - controlled, randomized trial European Myocardial Infarction Project - Free Radicals. Eur Heart J 2000; 21 (18): 1537-46.
  41. www.EMA/412151/2012 EMEA/H/A-31/130521. 2012
  42. Chaitman B.R, Pepine C.J, Parker J.O et al; Combination Assessment of Ranolazine In Stable Angina (CARISA). Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004; 291 (3): 309-16.
  43. Melloni C, Newby L.K. Metabolic efficiency with ranolazine forless ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. Exp Rev Cardiovasc Ther 2008; 6 (1): 9-16.
  44. Стаценко М.Е., Туркина С.В. Метаболическая кардиопротекция мельдонием у больных ишемической болезнью сердца: итоги и перспективы. Лечащий врач. 2012; 7: 96-103.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies